Anika Therapeutics (ANIK) Net Income towards Common Stockholders (QoQ) (2010 - 2025)
Anika Therapeutics (ANIK) Net Income towards Common Stockholders (QoQ) (2010 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Anika Therapeutics | 203.64 Mn | 136.85 Mn | 19.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -278.37% |
| Sep 30, 2025 | 24.96% |
| Jun 30, 2025 | 173.99% |
| Mar 31, 2025 | 95.28% |
| Dec 31, 2024 | 30.97% |
| Sep 30, 2024 | -1,244.44% |
| Jun 30, 2024 | 195.90% |
| Mar 31, 2024 | -116.51% |
| Dec 31, 2023 | 336.93% |
| Sep 30, 2023 | -136.06% |
| Jun 30, 2023 | 73.24% |
| Mar 31, 2023 | -185.15% |
| Dec 31, 2022 | 391.14% |
| Sep 30, 2022 | -46.85% |
| Jun 30, 2022 | 3.07% |
| Mar 31, 2022 | 72.64% |
| Dec 31, 2021 | -2,041.85% |
| Sep 30, 2021 | -91.55% |
| Jun 30, 2021 | 130.09% |
| Mar 31, 2021 | -71.81% |